Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Khan Fazal R.
 2. Date of Event Requiring Statement (Month/Day/Year)
01/31/2012		 3. Issuer Name and Ticker or Trading Symbol
MERRIMACK PHARMACEUTICALS INC [MACK]
(Last)
(First)
(Middle)
C/O MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP of Manufacturing
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CAMBRIDGE, MA 02139		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 02/24/2016 Common Stock 150,000 $ 1.71 D  
Stock Option (right to buy)   (1) 10/03/2016 Common Stock 23,412 $ 2.47 D  
Stock Option (right to buy)   (1) 10/03/2016 Common Stock 11,588 $ 2.47 D  
Stock Option (right to buy)   (1) 10/04/2017 Common Stock 21,946 $ 2.59 D  
Stock Option (right to buy)   (1) 10/04/2017 Common Stock 93,054 $ 2.59 D  
Stock Option (right to buy)   (1) 09/21/2018 Common Stock 262,500 $ 1.81 D  
Stock Option (right to buy)   (2) 11/04/2019 Common Stock 180,000 $ 2.12 D  
Stock Option (right to buy)   (3) 12/21/2020 Common Stock 50,000 $ 2.69 D  
Stock Option (right to buy)   (4) 05/02/2021 Common Stock 100,000 $ 5.54 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Khan Fazal R.
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201
CAMBRIDGE, MA 02139		       SVP of Manufacturing  

Signatures

/s/ Jeffrey A. Munsie, attorney-in-fact 02/01/2012
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This option is fully vested.
(2) This option vested as to 1/12th of the shares on each of November 5, 2009 and February 1, 2010 and vests in equal quarterly installments thereafter until August 1, 2012.
(3) This option vested as to 1/6th of the shares on January 1, 2011 and vests in equal quarterly installments thereafter until July 1, 2013.
(4) This option vested as to 1/12th of the shares on August 1, 2011 and vests in equal quarterly installments thereafter until May 1, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.